Class of Stock [Axis]
Common Stock, $0.001 par value per share
8.625% Senior Notes due 2026
Related Party [Axis]
Surface Ophthalmics [Member]
Melt Pharmaceuticals [Member]
Product and Service [Axis]
Product Sales, Net [Member]
Other Revenues [Member]
Eton Pharmaceuticals [Member]
Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Antidilutive Securities [Axis]
Warrant [Member]
Stock Options [Member]
Series [Axis]
Eton Pharmaceuticals, Inc. [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Melt Pharmaceuticals, Inc. [Member]
Surface Pharmaceuticals Inc [Member]
Commissions [Member]
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Management Services Agreement [Member]
Title of Individual [Axis]
Dr. Lindstrom [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Patents [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Licenses [Member]
Trademarks [Member]
Customer Relationships [Member]
Trade Names [Member]
Non-Competition Clause [Member]
State Pharmacy Licenses [Member]
Term Loan and Security Agreement [Member]
SWK Funding LLC [Member]
Variable Rate [Axis]
London Interbank Offered Rate (LIBOR) [Member]
Base Rate [Member]
SWK Second Amendment [Member]
Business Loan Agreement [Member]
Geographical [Axis]
San Diego [Member]
Ledgewood [Member]
Lease Contractual Term [Axis]
Additional Square Footage of Lease [Member]
Nashville [Member]
Mark L. Baum [Member]
Award Type [Axis]
Restricted Stock Units (RSUs) [Member]
Andrew R. Boll [Member]
Director [Member]
Series C Cumulative Preferred Stock [Member]
Plan Name [Axis]
2017 Incentive Stock and Awards Plan [Member]
Stock Option Plan [Member]
Stock Option Plan [Member]
Employees and Consultant [Member]
Options Granted to Employees [Member]
Exercise Price Range [Axis]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Employees [Member]
Unvested RSUs [Member]
Class of Warrant or Right [Axis]
Lender Warrants [Member]
Settlement Warrants [Member]
Lender Warrants One [Member]
Income Statement Location [Axis]
Selling, General and Administrative [Member]
Klarity License Agreement [Member]
Richard L. Lindstrom, M.D [Member]
Scenario [Axis]
Initial Payment [Member]
License Agreement [Member]
Second Payment [Member]
Final Payment [Member]
Injectable Asset Purchase Agreement [Member]
Dexycu Agreement [Member]
Sales and Marketing Agreements [Member]
Consolidation Items [Axis]
Operating Segments [Member]
Segments [Axis]
ImprimisRx [Member]
Pharmaceutical Drug Development [Member]
Corporate, Non-Segment [Member]
Research and Development Expense [Member]
Concentration Risk Type [Axis]
Three Main Suppliers [Member]
Eton Stock Sale [Member]
Sale of Stock [Axis]
Underwritten Public Offering [Member]
Debt Instrument [Axis]
8.625% Senior Notes Due 2026 [Member]
Underwriters [Member]
SWK Loan [Member]
Series B Cumulative Preferred Stock [Member]
Elle Pharmaceutical, LLC [Member]
Business Acquisition [Axis]
TGV-Health, LLC [Member]
Stowe Pharmaceuticals, Inc. [Member]
Statement [Table]
Affiliate, Collateralized Security [Line Items]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Schedule of Defined Benefit Plans Disclosures [Table]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
ASSETS
Current assets
Cash and cash equivalents, including restricted cash of $200
Investment in Eton Pharmaceuticals
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Investments
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of paycheck protection program loan payable
Current portion of loan payable, net of unamortized debt discount
Current portion of operating lease liabilities
Current portion of finance lease obligations
Total current liabilities
Operating lease liabilities, net of current portion
Finance lease obligations
Accrued expenses, net of current portion
Paycheck protection program loan payable, net of current portion
Loan payable, net of current portion and unamortized debt discount
TOTAL LIABILITIES
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY
Common stock, $0.001 par value, 50,000,000 shares authorized, 25,983,676 and 25,749,875 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively
Additional paid-in capital
Accumulated deficit
TOTAL HARROW HEALTH STOCKHOLDERS’ EQUITY
Noncontrolling interests
TOTAL EQUITY
TOTAL LIABILITIES AND EQUITY
Statement of Financial Position [Abstract]
Restricted Cash
Common stock, par value
Common stock, sharess authorized
Common stock, shares issued
Common stock, shares outstanding
Statement [Line Items]
Revenues:
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
Income (loss) from operations
Other income (expense):
Interest expense, net
Investment loss
Gain on forgiveness of debt
Total other (expense), net
Income (loss) before income taxes
Income taxes
Total net income (loss) including noncontrolling interests
Net loss attributable to noncontrolling interests
Net income (loss) attributable to Harrow Health, Inc.
Basic net income (loss) per share of common stock
Diluted net income (loss) per share of common stock
Weighted average number of shares of common stock outstanding, basic
Weighted average number of shares of common stock outstanding, diluted
Beginning balance, value
Balance, shares
Exercise of employee options
Exercise of employee options, shares
Issuance of common stock related to vesting of RSUs
Issuance of common stock related to vesting of RSUs, shares
Shares withheld related to net share settlement of equity awards
Shares withheld related to net share settlement of equity awards, shares
Stock-based compensation expense
Net income
Ending balance, value
Balance, shares
Statement of Cash Flows [Abstract]
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss) (including noncontrolling interests)
Adjustments to reconcile net income (loss) to net cash provided by (used in)
Depreciation and amortization of property, plant and equipment
Amortization of intangible assets
Amortization of operating lease right-of-use assets
Provision for bad debt expense
Amortization of debt issuance costs and discount
Gain on forgiveness of debt
Investment loss from Eton Pharmaceuticals
Investment loss from Surface Ophthalmics
Investment loss from Melt Pharmaceuticals
Stock-based compensation
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in patent and trademark assets
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations
Principal payments on SWK loan
Net proceeds from exercise of stock options, net of taxes remitted upon vesting of RSU’s and options
NET CASH USED IN FINANCING ACTIVITIES
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
Restricted cash
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right-of-use asset obtained in exchange for lease obligation
Changes in accrued property and equipment purchases
Accounting Policies [Abstract]
DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue from Contract with Customer [Abstract]
REVENUES
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN MELT PHARMACEUTICALS, INC. - RELATED PARTY TRANSACTIONS
Investment In Surface Ophthalmics Inc. - Related Party Transactions
INVESTMENT IN SURFACE OPHTHALMICS, INC. - RELATED PARTY TRANSACTIONS
Restricted Cash
RESTRICTED CASH
Inventory Disclosure [Abstract]
INVENTORIES
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Debt Disclosure [Abstract]
DEBT
Leases [Abstract]
LEASES
Equity [Abstract]
STOCKHOLDERS’ EQUITY AND STOCK-BASED COMPENSATION
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Segment Reporting [Abstract]
SEGMENT INFORMATION AND CONCENTRATIONS
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Risks, Uncertainties and Liquidity
Segments
Noncontrolling Interests
Basic and Diluted Net Income (Loss) per Common Share
Investment in Eton Pharmaceuticals, Inc.
Investment in Melt Pharmaceuticals, Inc. – Related Party
Investment in Surface Ophthalmics, Inc. – Related Party
Recently Adopted Accounting Pronouncements
SCHEDULE OF BASIC EARNINGS PER COMMON SHARE
SCHEDULE OF DILUTED COMMON EQUIVALENT SHARES
SCHEDULE OF DILUTED EARNINGS PER COMMON SHARE
SCHEDULE OF DISAGGREGATED REVENUE
SCHEDULE OF CONDENSED INCOME STATEMENT
SCHEDULE OF CONDENSED BALANCE SHEET
SUMMARY OF CONDENSED INCOME STATEMENT
SUMMARY OF CONDENSED BALANCE SHEET
SCHEDULE OF INVENTORIES
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT
SCHEDULE OF INTANGIBLE ASSETS
SCHEDULE OF AMORTIZATION EXPENSES FOR INTANGIBLE ASSETS
SCHEDULE OF ESTIMATED FUTURE AMORTIZATION EXPENSE
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES
SUMMARY OF FUTURE MINIMUM PAYMENTS
SCHEDULE OF FUTURE LEASE PAYMENTS UNDER OPERATING LEASES
SCHEDULE OF FUTURE LEASE PAYMENTS UNDER FINANCE LEASE
SCHEDULE OF STOCK OPTION PLAN ACTIVITY
SCHEDULE OF FAIR VALUE ASSUMPTIONS
SCHEDULE OF STOCK OPTION OUTSTANDING AND EXERCISABLE
SCHEDULE OF RESTRICTED STOCK UNITS ACTIVITY
SCHEDULE OF WARRANTS ACTIVITY
SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS EXERCISABLE
SCHEDULE OF STOCK BASED COMPENSATION GRANTED TO EMPLOYEES DIRECTORS CONSULTANTS
SCHEDULE OF SEGMENT NET REVENUES, SEGMENT OPERATING EXPENSES AND SEGMENT CONTRIBUTION
Consolidation basis, description
Numerator – net income (loss) attributable to Harrow Health, Inc.
Denominator – weighted average number of shares outstanding, basic
Net income (loss) per share, basic
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive common equivalent shares
Numerator – net income (loss)
Weighted average number of shares outstanding, basic
Dilutive common equivalent shares
Denominator – number of shares used for diluted earnings per share computation
Net income (loss) per share, diluted
Entity Listings [Line Items]
Non-controlling interest description
Unvested restricted stock units
Vested restricted stock units
Number of shares owned
Equity method investment, ownership percentage
Shares issued, price per share
Unrealized loss on investments
Investment owned, at fair value
Stock issued during period
Due from related parties
Disaggregation of Revenue [Table]
Disaggregation of Revenue [Line Items]
Total Revenues
Revenues, net
Loss from operations
Net loss
Current assets
Non-current assets
Total assets
Total liabilities
Total stockholders equity
Total liabilities and stockholders' equity
Administrative fees expense
Non current assets
Royalty payment percentage on net sales
Restricted cash
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Deposits and other current assets
Total prepaid expenses and other current assets
Computer software and hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Property, plant and equipment, gross
Accumulated depreciation and amortization
Property, plant and equipment, net
Depreciation and amortization, net
Schedule of Finite-Lived Intangible Assets [Table]
Finite-Lived Intangible Assets [Line Items]
Amortization periods (in years)
Cost
Accumulated amortization
Impairment
Net carrying value
Amortization periods description
Amortization of intangible assets
Remainder of 2021
2022
2023
2024
2025
Thereafter
Intangible assets
Accounts payable
Other accrued expenses
Accrued interest
Accrued exit fee for note payable
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Remainder of 2021
2022
2023
Total minimum payments
Less: amount representing interest
Notes payable, gross
Less: unamortized discount
Notes payable
Less: current portion, net of unamortized discount
Note payable, net of current portion and unamortized debt discount
Schedule of Long-term Debt Instruments [Table]
Debt Instrument [Line Items]
Debt principal amount
Debt instrument interest rate
Debt instrument interest rate description
Interest expense, debt
Amortization of debt discount (premium)
Gain on forgivness of debt
Remainder of 2021
2022
2023
2024
2025
Thereafter
Total minimum lease payments
Less: amount representing interest payments
Total operating lease liabilities
Less: current portion, operating lease liabilities
Remainder of 2021
2022
2023
2024
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payments
Less: current portion, finance lease obligation
Finance lease obligation, net of current portion
Lessee, Lease, Description [Table]
Lessee, Lease, Description [Line Items]
Operating lease space
Operating lease expires date
Lease term description
Weighted average incremental borrowing rate, operating lease
Weighted average remaining lease term, operating lease
Cash paid in operating lease liability
Operating lease expense
Weighted average incremental borrowing rate, finance lease
Weighted average remaining lease term, finance lease
Operating leases, income statement, depreciation expense on property subject to or held-for-lease
Finance lease, interest expense
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Number of shares, Options granted
Weighted Avg. Exercise Price, Options granted
Number of shares, Options exercised
Weighted Avg. Exercise Price, Options exercised
Number of shares, Options cancelled/forfeited
Weighted Avg. Exercise Price, Options cancelled/forfeited
Number of shares, Outstanding, Ending balance
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Remaining Contractual Life, Options outstanding
Aggregate Intrinsic Value, Options outstanding
Number of shares, Options exercisable
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Remaining Contractual Life, Options exercisable
Aggregate Intrinsic Value, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Dividend yield
Share-based Payment Arrangement, Option, Exercise Price Range [Table]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Weighted Average Grant Date Fair Value, Beginning balance
Number of RSUs granted
Weighted Average Grant Date Fair Value, RSUs granted
Number of RSUs vested
Weighted Average Grant Date Fair Value, RSUs vested
Number of RSUs cancelled/forfeited
Weighted Average Grant Date Fair Value, RSUs cancelled/forfeited
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Ending balance
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Number of Shares Warrants Outstanding, beginning balance
Weighted Avg. Exercise Price, Outstanding, beginning balance
Number of Shares Warrants Outstanding, Granted
Number of Shares Warrants Outstanding, Exercised
Number of Shares Warrants Outstanding, Expired
Number of Shares Warrants Outstanding and Exercisable, ending balance
Weighted Avg. Exercise Price, Outstanding and Exercisable, ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Warrants issuance date
Class of Warrant or Right, Outstanding
Class of Warrant or Right, Exercise Price of Warrants or Rights
Expiration Date
Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Share-based Payment Arrangement, Expense
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares isssued
Number of options to purchase common stock
Exercise price, minimum
Exercise price, maximum
Net proceeds received
Shares issued of restricted common stock, shares
Number of stock withheld for payroll tax purposes
Value of stock withheld for payroll tax purposes
Preferred stock, shares authorized
Preferred stock, par value
Preferred stock, shares outstanding
Number of shared sold
Gross proceeds from stock issued
Maximum number of common stock issuance under the plan
Shares available for future issuances
Closing price of common stock price per share
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Share-based compensation arrangement by share-based payment award, plan modification, description and terms
Unrecognized compensation expense related to unvested stock options granted under the plan
Weighted-average period for recognition
Intrinsic value of options exercised
Number of restrcited shares, value
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Royalty payment description
Royalty payments
Sales revenue net
Milestone payments on payables
Milestone payment in cash
Commission expense incurred
Commission payments percentage
Stock based payments
Business acquisition description
Schedule of Segment Reporting Information, by Segment [Table]
Segment Reporting Information [Line Items]
Cost of sales
Gross profit
Segment contribution
Operating income (loss)
Amortization
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Revenue, Major Customer [Line Items]
Number of operating segments, description.
Percentage of sales derived from large number of customer
Subsequent Event [Table]
Subsequent Event [Line Items]
Number of common stock shares issued
Number of shares vested
Value of shares issued
Options to purchase shares of common stock
Exercise price per share
Proceeds from purchase of common stock
Number of public offering shares issued
Offering price per share
Proceeds from offering
Owned shares
Equity voting interest percentage
Debt interest rate
Debt maturity date
Debt redemption percentage
Repayment of loan
Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Liquidation Preference Per Share
Preferred stock description
Preferred Stock, Dividend Rate, Percentage
Share price per share
Number of shares returned
8.625% Senior Notes due 2026.
Common Stock, $0.001 par value per share.
Surface Ophthalmics [Member].
Melt Pharmaceuticals [Member]
Gain on forgiveness of debt.
Product Sales, Net [Member]
Other Revenues [Member]
Eton Pharmaceuticals [Member]
Amortization of intangible assets.
Amortization of operating lease right-of-use assets.
Investment loss one.
Investment loss two.
Investment loss three.
Net proceeds from exercise of stock options, net of taxes remitted upon vesting of RSU’s and options
Cash, Cash Equivalents And Restricted Cash At End Of Period.
Right-of-use asset obtained in exchange for lease obligation.
Changes in accrued property and equipment purchases.
Consolidation basis, description.
Unvested restricted stock units.
Vested restricted stock units.
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Stock Options [Member]
Incremental Common Shares Attributable to Dilutive common equivalents.
Noncontrolling Interests [Policy Text Block]
Investment [Policy Text Block]
Investment [Policy Text Block]
Recently Adopted Accounting Pronouncements [Policy Text Block]
Risks, Uncertainties and Liquidity [Policy Text Block]
Number of shares owned.
Eton Pharmaceuticals, Inc. [Member]
Melt Pharmaceuticals, Inc. [Member]
Surface Pharmaceuticals Inc [Member]
Commissions [Member]
Management Services Agreement [Member]
Schedule of Condensed Balance Sheet [Table Text Block]
Schedule of Condensed Balance Sheet [Table Text Block]
Investment in Surface Ophthalmics, Inc. and Agreements - Related Party Transactions [Text Block]
Royalty payment percentage on net sales.
Dr. Lindstrom [Member]
Restricted Cash [Text Block]
Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]
Licenses [Member]
State Pharmacy Licenses [Member]
Non-Competition Clause [Member]
Finite Lived Intangible Assets Impairment.
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Term Loan and Security Agreement [Member]
SWK Funding LLC [Member]
SWK Second Amendment [Member]
Business Loan Agreement [Member]
Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
San Diego [Member]
Ledgewood [Member]
Additional Square Footage of Lease [Member]
Nashville [Member]
Lease expiration date description.
Weighted average incremental borrowing rate, operating lease.
Cash paid in operating lease liability.
Weighted average incremental borrowing rate, finance lease.
Mark L. Baum [Member]
Andrew R. Boll [Member]
Series C Cumulative Preferred Stock [Member]
2017 Incentive Stock and Awards Plan [Member]
Closing price of common stock price per share.
Stock Option Plan [Member]
Employees and Consultant [Member]
Employees [Member]
Unvested RSUs [Member]
Stock Option Plan [Member]
Options Granted to Employees [Member]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Schedule of Warrants Outstanding and Warrants Exercisable [Table Text Block]
Number of shares warrants outstanding and exercisable, ending balance.
Sharebased compensation arrangement by sharebased payment award non options outstanding weighted average remaining contractual term.
Share based compensation arrangement by share based payment award non options equity instruments outstanding weighted average exercise price.
Share based compensation arrangement by share based payment award non options equity instruments outstanding and exercisable weighted average exercise price.
Warrants issuance date.
Lender Warrants [Member]
Settlement Warrants [Member]
Lender Warrants One [Member]
Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.
Selling, General and Administrative [Member]
Royalty payment description.
Klarity License Agreement [Member]
Richard L. Lindstrom, M.D [Member]
Initial Payment [Member]
License Agreement [Member]
Second Payment [Member]
Final Payment [Member]
Net sales of product.
Milestone payment in cash.
Injectable Asset Purchase Agreement [Member]
Dexycu Agreement [Member]
Commission payments, percentage.
Sales and Marketing Agreements [Member]
Number of operating segments, description.
Three Main Suppliers [Member]
ImprimisRx [Member]
Segment contribution.
Pharmaceutical Drug Development [Member]
Eton Stock Sale [Member]
Underwritten Public Offering [Member]
8.625% Senior Notes Due 2026 [Member]
Underwriters [Member]
SWK Loan [Member]
Series B Cumulative Preferred Stock [Member]
TGV-Health, LLC [Member]
Elle Pharmaceutical, LLC [Member]
Stowe Pharmaceuticals, Inc. [Member]
Stock Option Plan [Member] [Default Label]
Assets, Current
Liabilities, Current
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Operating Expenses
Nonoperating Income (Expense)
Net Income (Loss) Attributable to Noncontrolling Interest
Shares, Outstanding
GainLossOnInvestmentsOne
GainLossOnInvestmentsTwo
GainLossOnInvestmentsThree
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Contract with Customer, Liability
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Intangible Assets
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Finance Lease, Principal Payments
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
CashCashEquivalentsAndRestrictedCashAtEndOfPeriod
Commitments and Contingencies Disclosure [Text Block]
Dilutive common equivalent shares [Default Label]
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Amortization of Intangible Assets
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Long-Term Debt, Maturity, Remainder of Fiscal Year
Long-Term Debt, Maturity, Year One
Long-Term Debt, Maturity, Year Two
Long-term Debt
Interest Payable, Current
Debt Instrument, Unamortized Discount
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Finance Lease, Liability, to be Paid, Remainder of Fiscal Year
Finance Lease, Liability, to be Paid, Year One
Finance Lease, Liability, to be Paid, Year Two
Finance Lease, Liability, to be Paid, Year Three
Finance Lease, Liability, Payment, Due
Finance Lease, Liability, Undiscounted Excess Amount
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Weighted Avg. Exercise Price, Outstanding, beginning balance
Number of Shares Warrants Outstanding and Exercisable, ending balance
Warrant